[1]王单,陈玉成.左心疾病相关性肺动脉高压临床研究进展[J].心血管病学进展,2023,(11):996.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.009]
　WANG Dan,CHEN Yucheng.Clinical Research Progress of Pulmonary Hypertension Associated with Left Heart Disease[J].Advances in Cardiovascular Diseases,2023,(11):996.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.009]
点击复制

左心疾病相关性肺动脉高压临床研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年11期
页码:
996
栏目:
综述
出版日期:
2023-11-25

文章信息/Info

Title:
Clinical Research Progress of Pulmonary Hypertension Associated with Left Heart Disease
作者:
王单1; 2;  陈玉成1
(1四川大学华西医院心内科,四川 成都 610041;2四川大学华西空港医院心内科,四川成都 610200)
Author(s):
WANG Dan1; 2;  CHEN Yucheng1
(1.Department of Cardiology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China; 2.Department of Cardiology,West China(Airport) Hospital,Sichuan University,Chengdu 610200,Sichuan,China)
关键词:
肺动脉高压; 左心疾病; 诊断; 治疗
Keywords:
Pulmonary hypertension; Left heart disease; Diagnosis; Treatment
DOI:
10.16806/j.cnki.issn.1004-3934.2023.11.009
摘要:
肺动脉高压是一大类进展性、致残率和致死率极高的疾病。左心疾病相关性肺动脉高压最为常见，其病情更重、预后更差、病死率更高，严重影响患者生活质量。目前该类肺动脉高压的流行病学数据不清楚、临床诊断标准不统一、病理生理机制不甚明确、分类方法存在争议、靶向药物治疗缺乏证据，国内外相关研究和治疗十分有限。现概述左心疾病相关性肺动脉高压的定义及分类、流行病学、病因及发病机制、病理生理机制，并详细阐述其诊断及特异性治疗的临床研究进展。
Abstract:
Pulmonary hypertension is a major progressive,highly disabling and fatal disease. Pulmonary hypertension associated with left heart disease is the most common,with a more severe condition,poorer prognosis and higher mortality rate,seriously affecting the quality of life of patients. At present,the epidemiological data of this type of pulmonary hypertension is unclear,clinical diagnostic standards are not unified,pathological and physiological mechanisms are not clear,classification methods are controversial,and there is a lack of evidence for targeted drug therapy. The research and treatment at home and abroad are very limited. This paper review s the definition,epidemiology,etiology,pathogenesis and pathophysiology of pulmonary hypertension associated with left heart disease,and elaborate the clinical research progress in its diagnosis and specific treatment

参考文献/References:

[1] Humbert M,Kovacs G,Hoeper MM,et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J,2023,61(1):2200879.

[2] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南（2021版）[J]. 中华医学杂志,2021, 101(1):11-51.

[3] 国家心血管病中心肺动脉高压专科联盟国家,心血管病专家委员会右心与肺血管病专业委员会. 中国肺动脉高压诊治临床路径[J]. 中国循环杂志,2023,38(7):691-703.

[4] Rao SD,Adusumalli S,Mazurek JA. Corrigendum to:pulmonary hypertension in heart failure patients[J]. Heart Fail Rev,2020,6:e30.

[5] Maron BA,Brittain EL,Hess E,et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension:a retrospective cohort study[J]. Lancet Respir Med,2020,8(9):873-884.

[6] Bermejo J,González‐Mansilla A,Mombiela T,et al. Persistent pulmonary hypertension in corrected valvular heart disease:hemodynamic insights and long‐term survival[J]. J Am H eart A ssoc,2021,10(2):e019949.

[7] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 ACC/AHA/HFSA guideline for the management of heart failure[J]. J Card Fail,2022,28(5):e1-e167.

[8] Xiao M,Lai D,Yu Y,et al. Pathogenesis of pulmonary hypertension caused by left heart disease[J]. Front Cardiovasc Med,2023,10:1079142.

[9] Kurakula K,Smolders VFED,Tura-Ceide O,et al. Endothelial dysfunction in pulmonary hypertension:cause or consequence?[J]. Biomedicines,2021,9(1):57.

[10] Maclean MR,Fanburg B,Hill N,et al. Serotonin and pulmonary hypertension;sex and drugs and ROCK and rho[J]. Compr Physiol,2022,12(4):4103-4118.

[11] Lambert M,Mendes-Ferreira P,Ghigna MR,et al. Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload[J]. Cardiovasc Res,2021,117(12):2474-2488.

[12] Jang AY,Park SJ,Chung WJ. Pulmonary hypertension in heart failure[J]. Int J Heart Fail,2021,3(3):147-159.

[13] Wissmüller M,Dohr J,Adler J,et al. Pulmonary hypertension associated with left heart disease[J]. Herz,2023,48(4):266-273.

[14] Lee F,Mielniczuk LM. Pulmonary hypertension due to left heart disease—A practical approach to diagnosis and management[J]. Can J Cardiol,2021,37(4):572-584.

[15] Redfield MM,Borlaug BA. Heart failure with preserved ejection fraction:a review[J]. JAMA,2023,329(10):827-838.

[16] Desai AS,Lam CSP,Mcmurray JJV,et al. How to manage heart failure with preserved ejection fraction[J]. JACC Heart Fail,2023,11(6):619-636.

[17] Kusunose K,Yamada N,Yamada H,et al. Association between right ventricular contractile function and cardiac events in isolated postcapillary and combined pre- and postcapillary pulmonary hypertension[J]. J Card Fail,2020,26(1):43-51.

[18] Colin GC,Pouleur AC,Gerber BL,et al. Pulmonary hypertension detection by computed tomography pulmonary transit time in heart failure with reduced ejection fraction[J]. Eur Heart J,2020,21(11):1291-1298.

[19] Melzig C,Do TD,Egenlauf B,et al. [Diagnostic accuracy of automated 3D volumetry of cardiac chambers by CT pulmonary angiography for identification of pulmonary hypertension due to left heart diseaseJ]. Eur Radiol,2022,32(8):5222-5232.

[20] Gong C,Guo X,Wan K,et al. Corrected MRI pulmonary transit time for identification of combined precapillary and postcapillary pulmonary hypertension in patients with left heart disease[J]. J Magn Reson Imaging,2022,57(5):1518-1528.

[21] Hameed A,Condliffe R,Swift AJ,et al. Assessment of right ventricular function—A state of the art[J]. Curr Heart Fail Rep,2023,20(3):194-207.

[22] Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease[J]. EuroIntervention,2022,17(14):e1126-e1196.

[23] Ltaief Z,Yerly P,Liaudet L. Pulmonary hypertension in left heart diseases:pathophysiology,hemodynamic assessment and therapeutic management[J]. Int J Mol Sci,2023,24(12):9971.

[24] Awada C,Boucherat O,Provencher S,et al. The future of group 2 pulmonary hypertension:exploring clinical trials and therapeutic targets[J]. Vascul Pharmacol,2023,151:107180.

[25] Frantz RP. Group 2 pulmonary hypertension:from diagnosis to treatment[J]. Curr Opin Pulm Med,2023,29(5):391-398.

[26] Lteif C,Ataya A,Duarte JD. Therapeutic challenges and emerging treatment targets for pulmonary hypertension in left heart disease[J]. J Am Heart Assoc,2021,10(11):e020633.

[27] Oral nitrite in patients with pulmonary hypertension and heart failure with preserved ejection fraction(ph-hfpef)[EB/OL].(2017-01-10)[2023-01-22].https://clinicaltrials.gov/ct2/show/NCT03015402.

[28] Dachs TM,Duca F,Rettl R,et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction:the haemodynamic trial[J]. Eur Heart J,2022,43(36):3402-3413.

[29] Cooper TJ,Cleland JGF,Guazzi M,et al. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension(the SilHF study): a randomized placebo-controlled multicentre trial[J]. Eur J Heart Fail,2022,24(7):1239-1248.

[30] Wang L,Halliday G,Huot JR,et al. Treatment with treprostinil and metformin normalizes hyperglycemia and improves cardiac function in pulmonary hypertension associated with heart failure with preserved ejection fraction[J]. Arterioscler Thromb Vasc Biol,2020,40(6):1543-1558.

[31] Ranchoux B,Nadeau V,Bourgeois A,et al. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease[J]. Circ Res,2019,125(4):449-466.

[32] Chomette L,Caravita S,Dewachter C,et al. Pulmonary arterial hypertension‐associated genetic variants in combined post‐capillary and pre‐capillary pulmonary hypertension:a case report[J]. Pulm Circ,2021,11( 1):1-5.

[33] Hoeper MM,Badesch DB,Ghofrani HA,et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension[J]. N Engl J Med,2023,388(16):1478-1490.

[34] A study of sotatercept for the treatment of cpc-ph due to hfpef (mk-7962-007/a011-16) (cadence)[EB/OL]. (2021-06-30)[2023-01-22]. https://clinicaltrials.gov/ct2/show/NCT04945460.

[35] Padn-cfda:pulmonary artery denervation shows promise for treating pah[EB/OL]. (2022-09-18)[2023-01-22]. https://www.acc.org/latest-in-cardiology/articles/2022/09/16/18/24/sun-1215pm-padn-cfda-tct-2022.

[36] Adler J,Gerhardt F,Wissmüller M,et al. Pulmonary hypertension associated with left-sided heart failure[J]. Curr O pin C ardiol,2020,35(6):610-619.

[37] Zhang H,Zhang J,Chen M,et al. Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure[J]. JACC Cardiovasc Interv,2019,12(3):274-284.

[38] Zhang H,Kan J,Zhang J,et al. 3-Year outcome in patients with combined precapillary and postcapillary pulmonary hypertension:results from PADN-5 trial[J]. JACC Heart Fail,2023,11(8 Pt 2):1135-1146.

[39] Treatment of pulmonary hypertension group Ⅱ study (trophy- Ⅱ)[EB/OL]. (2018-08-02)[2023-01-22]. https://clinicaltrials.gov/ct2/show/NCT03611270.

[40] Kennedy JLW,Mihalek AD. Update in approaches to pulmonary hypertension because of left heart disease[J]. Curr Opin Pulm Med,2022,28(5):337-342.

相似文献/References:

[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
　MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(11):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
　ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(11):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
　WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(11):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
　WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(11):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
　DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(11):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
　ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(11):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
　ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(11):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
　HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(11):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
　LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(11):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
　Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(11):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]

更新日期/Last Update: 2023-12-13